Guobang Pharma Ltd (605507.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100004NS2
Guobang Pharma Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.89 bn CNY | 6.01 bn CNY |
| Gross profit | 1.44 bn CNY | 1.56 bn CNY |
| Operating income | 895.07 m CNY | 961.88 m CNY |
| EBIT | 836.84 m CNY | 975.18 m CNY |
| Net income | 781.60 m CNY | 820.82 m CNY |
| Diluted EPS – continuing operations | 1.40 CNY | 1.05 CNY |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The company was founded in 1996 and is based in Xinchang, China.
More stocks
- Jiangsu Toland Alloy Co Ltd (300855.SZ)
- BGF Retail Co Ltd (282330.KS)
- Greencore Group PLC (GNC.L)
- Shangri-La Asia Ltd (69.HK)
- Resolute Mining Ltd (RSG.AX)
- China Marine Information Electronics Co Ltd (600764.SS)
- HC Semitek Corp (300323.SZ)
- Hydsoft Technology Co. Ltd. A (301316.SZ)
- Sumber Global Energy Tbk Pt (SGER.JK)
- HBM Healthcare Investments (HBMN.SW)
- Dgb Financial (139130.KS)
- Jiangsu Lopal Tech Co Ltd (603906.SS)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.